WALTHAM, Mass., March 19, 2015 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat Central Nervous System (CNS) diseases and disorders, today announced that it will release fourth quarter and full year 2014 financial results after market close on Thursday, March 26, 2015. Minerva management will host a webcast and conference call the same day at 4:30 p.m. EDT to discuss the financial results and business highlights.
The live call may be accessed by dialing (877) 312-5845 for domestic callers or (765) 507-2618 for international callers, and by referencing conference ID number 9756969. A live webcast of the conference call will be available online from the investor relations section of the company's website at http://ir.minervaneurosciences.com/. The webcast will be archived on the company's website for 30 days.
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat CNS diseases. Minerva is developing first-in-class proprietary compounds, including its lead program MIN-101 in development for the treatment of schizophrenia, MIN-202 in development for primary and comorbid insomnia, MIN-117 in development for the treatment of major depressive disorder and MIN-301 in development for the treatment of Parkinson's disease. Minerva's common stock is listed on the NASDAQ Global Market where it trades under the symbol "NERV". For more information, please visit www.minervaneurosciences.com/.
CONTACT: Media Contact: Bill Berry Berry & Company Public Relations 212-253-8881 firstname.lastname@example.org Investor Contact: Renee Leck Stern Investor Relations Tel: 212-362-1200 email@example.comSource:Minerva Neurosciences, Inc